Immunocore Holdings Limited (IMCR)
| Market Cap | 2.09B |
| Revenue (ttm) | 36.61M |
| Net Income (ttm) | -104.89M |
| Shares Out | 41.72M |
| EPS (ttm) | -2.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $41.25 |
| Previous Close | $49.31 |
| Change ($) | -8.06 |
| Change (%) | -16.35% |
| Day's Open | 49.15 |
| Day's Range | 40.00 - 49.15 |
| Day's Volume | 112,035 |
| 52-Week Range | 39.02 - 61.99 |
News
The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresecta...
About IMCR
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cance... [Read more...]
| Industry Biotechnology | IPO Date Feb 5, 2021 |
| CEO Bahija Jallal, Ph.D. | Employees 291 |
| Stock Exchange NASDAQ | Ticker Symbol IMCR |
Financial Performance
In 2019, Immunocore's revenue was 25.67 million, an increase of 8.52% compared to the previous year's 23.65 million. Losses were -103.93 million, 45.1% more than in 2018.